Search research articles
Contact Us
Filters
Showing results (1-10 of 145) with videos related to
Page
of 15
Sort By:
Expert Opinion on Drug Safety
|
November 17, 2015
A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis
Nico M Wulffraat
Expert Opinion on Biological Therapy
|
March 5, 2013
Canakinumab in pediatric rheumatic diseases
Nico M Wulffraat, Patricia Woo
Pediatric Rheumatology Online Journal
|
February 19, 2013
Time to share
Nico M Wulffraat, Bas Vastert,
The Israel Medical Association Journal : IMAJ
|
October 14, 2008
Diagnostic workup for mixed connective tissue disease in childhood
Joost F Swart, Nico M Wulffraat
Expert Review of Clinical Immunology
|
May 27, 2014
Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment
Maja Bulatović Ćalasan, Nico M Wulffraat
Current Rheumatology Reports
|
May 31, 2015
Vaccinations in paediatric rheumatology: an update on current developments
Noortje Groot, Marloes W Heijstek, Nico M Wulffraat
Pediatric Rheumatology Online Journal
|
December 20, 2014
Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
E H Pieter van Dijkhuizen, Nico M Wulffraat
Annals of the Rheumatic Diseases
|
June 26, 2014
Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review
E H Pieter van Dijkhuizen, Nico M Wulffraat
Expert Reviews in Molecular Medicine
|
November 17, 2006
Refractory juvenile idiopathic arthritis: using autologous stem cell transplantation as a treatment strategy
Nico M Wulffraat, Ismé M de Kleer, Berent Prakken
Arthritis Research & Therapy
|
June 5, 2013
What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
Joost F Swart, Sytze de Roock, Nico M Wulffraat
Page
of 15
Search research articles
Search
Showing results (1-10 of 145) with videos related to
Sort By:
Page
of 15
Expert Opinion on Drug Safety
|
November 17, 2015
A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis
Nico M Wulffraat
Expert Opinion on Biological Therapy
|
March 5, 2013
Canakinumab in pediatric rheumatic diseases
Nico M Wulffraat, Patricia Woo
Pediatric Rheumatology Online Journal
|
February 19, 2013
Time to share
Nico M Wulffraat, Bas Vastert,
The Israel Medical Association Journal : IMAJ
|
October 14, 2008
Diagnostic workup for mixed connective tissue disease in childhood
Joost F Swart, Nico M Wulffraat
Expert Review of Clinical Immunology
|
May 27, 2014
Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment
Maja Bulatović Ćalasan, Nico M Wulffraat
Current Rheumatology Reports
|
May 31, 2015
Vaccinations in paediatric rheumatology: an update on current developments
Noortje Groot, Marloes W Heijstek, Nico M Wulffraat
Pediatric Rheumatology Online Journal
|
December 20, 2014
Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
E H Pieter van Dijkhuizen, Nico M Wulffraat
Annals of the Rheumatic Diseases
|
June 26, 2014
Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review
E H Pieter van Dijkhuizen, Nico M Wulffraat
Expert Reviews in Molecular Medicine
|
November 17, 2006
Refractory juvenile idiopathic arthritis: using autologous stem cell transplantation as a treatment strategy
Nico M Wulffraat, Ismé M de Kleer, Berent Prakken
Arthritis Research & Therapy
|
June 5, 2013
What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
Joost F Swart, Sytze de Roock, Nico M Wulffraat
Page
of 15